Compare Novavax Inc (NVAX) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Tyson Foods, Inc. — how do they compare? Novavax Inc trades at $12.83 (market cap $1.82B), while Tyson Foods, Inc. trades at $52.79 (market cap $18.41B). The key difference: Tyson Foods, Inc. is far larger — about 10.1× Novavax Inc's market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Tyson Foods, Inc. for 76 Days on average.
| NVAX | TSN | |
|---|---|---|
Market Cap | $1.82B | $18.41B |
Volume | 6,198,505 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $12.56 | $68.75 |
52-Week Low | $6.22 | $50.47 |
Typical Hold Time | 59 Days | 76 Days |
Enterprise Value | $1.39B | $25.68B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Tyson Foods (TSN) trades at $52.70, up 1.93% with mixed technical signals showing bullish overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99 beating expectations, though revenue growth remains modest at 1.5%-2.0% for 2026. Analysts maintain a Buy consensus with $65.40 target, but recent news highlights investigations into guidance revisions and beef segment challenges.
Outlook remains cautious with upside potential from execution improvements, but risks include beef segment losses, margin pressure, and ongoing securities investigations. The stock offers value with low P/S of 0.33 and consistent dividends, but requires monitoring of operational turnaround and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
